Immunogenicity of pneumococcal conjugate vaccines

Pediatric Infectious Disease Journal

Volumn 19, Issue 4, 2000, Pages 388-393

  Eskola, Juhani ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Anamnestic response; Functional activity; Immunogenicity; Immunologic memory; Pneumococcal conjugate vaccine; Pneumococcal polysaccharides

Indexed keywords

DIPHTHERIA TOXOID; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHILD; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0033999821     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200004000-00035     Document Type: Review

References (41)

1. Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J 1999;18:638-46.
2. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin S, Orenstain W, eds. Vaccines. Philadelphia: Saunders, 1999.
3. McIntyre P. Epidemiology and prevention of pneumococcal infections. Curr Opin Pediatr 1997;9:9-13.
4. Mulholland K. Magnitude of the problem of childhood pneumonia. Lancet 1999;354:590-2.
5. World Health Organization. Programme for the control of acute respiratory infections: pneumococcal conjugate vaccines. Report WHO/ARI/94.34. In: WHO Meeting, Geneva, Switzerland, 1994.
6. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46:1-24.
7. Barry AL. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. Am J Med 1999;26:28S-33S.
8. Klugman KP, Madhi SA. Emergence of drug resistance: impact on bacterial meningitis. Infect Dis Clin North Am 1999;13:637-46.
9. Cohen J. Bumps on the vaccine road. Science 1994;265: 1371-3.
10. Committee to Study Priorities for Vaccine Development. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st century: a tool for decisionmaking. Institute of Medicine (IOM), 1999.
11. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
12. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999;18:543-51.
13. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
14. Makela PH, Sibakov M, Herva E, et al. Pneumococcal vaccine and otitis media. Lancet 1980;2:547-51.
15. Karma P, Pukander J, Sipila M, et al. Prevention of otitis media in children by pneumococcal vaccination. Am J Otolaryngol 1985;6:173-84.
16. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986;2:877-81.
17. Ekdahl K, Braconier JH, Svanborg C. Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection. Clin Infect Dis 1997;25:654-60.
18. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998;30:597-601.
19. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(Suppl 1):S49-52.
20. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76.
21. Frasch C. Haemophilus influenzae type b conjugate and combination vaccines. Clin Immunother 1995;4:376-86.
22. Klein DL, Ellis RW. Conjugate vaccines against Streptococcus pneumoniae. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. New York: Marcel Dekker, 1997:503-25.
23. Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;2: 134-9.
24. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101(4 Part 1):604-11.
25. Kayhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis 1996;2:289-98.
26. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128(5 Part 1):649-53.
27. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;3:211-6.
28. Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997;16:1053-9.
29. Obaro SK, Huo Z, Banya WA, et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
30. Sigurdardottir ST, Vidarsson G, Gudnason T, et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997;16:667-74.
31. Anttila M, Eskola J, Käyhty H. Opsonic activity and concentration of antibodies to Streptococcus pneumoniae type 6B [Abstract 599]. In: 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September, 1997.
32. Vidarsson G, Sigurdardottir ST, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66: 2866-70.
33. Usinger W and Lucas A. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366-70.
34. Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG sub-classes and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999;118:402-7.
35. Anttila M, Eskola J, Ahman H, Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17: 1970-7.
36. Anttila M, Eskola J, Ahman H, Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177:1614-21.
37. Soininen A, Seppala I, Nieminen T, Eskola J, Kayhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 1999;17: 1889-97.
38. King JC Jr, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998;16:361-5.
39. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 1999;29: 191-2.
40. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998;17:685-91.
41. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large-scale field trials. Pediatr Infect Dis J 2000; 19:394-7.